Companies Attending Include:
Advancing Next Generation Radioligand Candidates to Commercialisation Through Rigorous Clinical Rationale, Novel Target Selection & Reliable Supply Chain Design
Ushering In the New Age of Targeted Radiopharmaceuticals
There has been so much progress in the TRP field recently with Novartis’s Lutathera hitting the primary endpoint in a Phase III trial, Genentech partnering up with PeptiDream to enter the radiopharma space, Eli Lilly’s billion-dollar deal to buy Point Biopharma and so much more!
The 5th Targeted Radiopharmaceuticals Summit is back and is bringing to you never seen before speakers from the likes of Novartis, Bayer, AstraZeneca, Bicycle Therapeutics and more, all of whom will delve into all of your challenges whether its related to discovering novel targets to transform your TRP development, working with low isotope availability to ensure you can meet tight manufacturing timelines, selecting the right target molecule to increase tumour targeting accuracy, answering regulatory questions, transitioning your molecule through the clinic or understanding the investor landscape, this conference has it all.
Attend this conference to master the complexity of TRPs by meeting the specific needs of the patient and taking TRPs to the front line of cancer treatment to make a difference.